MERS vaccine candidate: Safe, induced a robust immune response in Phase 1 trial
by Press Release from Outbreak News Today on (#4KVZ6)
A Middle East respiratory syndrome coronavirus (MERS CoV) vaccine candidate was shown to be safe, well-tolerated, and induced a robust immune response in a Phase 1 first-in-human clinical trial. Initial findings from the trial were published today in The Lancet Infectious Diseases. The study, conducted at the Walter Reed Army Institute of Research (WRAIR) Clinical Trials ["]
The post MERS vaccine candidate: Safe, induced a robust immune response in Phase 1 trial appeared first on Outbreak News Today.